Actively Recruiting

Phase 4
All Genders
NCT05067868

A Study of Replagal in Children and Adults With Fabry Disease in India

Led by Shire · Updated on 2025-09-19

5

Participants Needed

3

Research Sites

212 weeks

Total Duration

On this page

Sponsors

S

Shire

Lead Sponsor

T

Takeda

Collaborating Sponsor

AI-Summary

What this Trial Is About

The main aim of this study is to learn more about the safety profile of Replagal. Participants will receive Replagal every 2 weeks at the clinic for about 1 year.

CONDITIONS

Official Title

A Study of Replagal in Children and Adults With Fabry Disease in India

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male and female participants of any age with confirmed Fabry disease diagnosis who have not received Replagal before and are not in any other free enzyme replacement therapy program
  • Confirmed diagnosis based on gene mutation of alpha-galactosidase A or enzyme deficiency levels as specified
  • Presence of clinical symptoms of Fabry disease as determined by the investigator
  • Ability to understand and provide written informed consent or assent through a legal representative or guardian
  • Female participants of childbearing potential must have a negative pregnancy test before starting treatment and agree to use two forms of contraception during the study
  • Male participants who are sexually active with partners of childbearing potential must agree to use barrier contraception during the study
Not Eligible

You will not qualify if you...

  • Previous treatment with Replagal
  • Poorly controlled high blood pressure as determined by the investigator
  • Chronic kidney disease with very low kidney function (eGFR less than 15 mL/min/1.73 m²), history of kidney transplant, or current dialysis
  • Serious liver disorders with abnormal liver test results exceeding defined limits and considered clinically significant
  • Pregnant, breastfeeding, or intending to become pregnant or donate eggs during the study period for female participants
  • Inability to understand the study or provide informed consent
  • Inability or unwillingness to comply with study procedures or return for follow-up visits
  • Intent to donate sperm during the study for male participants
  • Participation in any other investigational drug trial within 4 weeks prior to screening
  • Any other condition judged by the investigator to make the participant unsuitable for the trial

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Institute of Child Health

Kolkata, India, 700017

Not Yet Recruiting

2

All India Institute of Medical Sciences (AIIMS)

New Delhi, India, 110029

Actively Recruiting

3

Sir Gangaram Hospital

New Delhi, India, 110060

Actively Recruiting

Loading map...

Research Team

T

Takeda Contact

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here